Phase I Primary Objective:
* Determine the maximum tolerated dose (MTD) of combination therapy with Aroplatin and gemcitabine (Gemzar®) in subjects with unresectable, locally advanced and/or metastatic pancreatic cancer.
Phase II Primary Objective:
* Evaluate survival after therapy with Aroplatin and gemcitabine at the MTD in subjects with unresectable, locally advanced and/or metastatic pancreatic cancer.
Phase II Secondary Objective:
* Evaluate the severity and quantity of adverse events and determine the proportion of non-progressors and the progression-free interval.
